Cialis and Viagra beyond ED: the blood pressure, heart, and brain evidence.

The PDE5 mechanism — why these drugs are vascular

Sildenafil and tadalafil are PDE5 inhibitors (PDE5i — phosphodiesterase type 5 inhibitors, drugs that block the enzyme responsible for degrading cyclic guanosine monophosphate, or cGMP, in vascular smooth muscle). The mechanism is straightforward and entirely vascular at its core. Nitric oxide (NO) is released by endothelial cells (the single-cell-thick lining of blood vessels) in response to shear stress, acetylcholine, and other signals. NO diffuses into the adjacent smooth muscle layer of the blood vessel and activates guanylate cyclase, which produces cGMP. cGMP relaxes the smooth muscle, which dilates the vessel and increases blood flow.

PDE5 is the enzyme that breaks cGMP back down. By inhibiting PDE5, sildenafil and tadalafil prolong the cGMP signal — leading to more sustained smooth muscle relaxation and vasodilation. This effect is most pronounced in tissues that express PDE5 most heavily: the corpus cavernosum of the penis (which is why the drugs work for erections), the pulmonary vasculature (which is why they treat pulmonary hypertension), and the smooth muscle of the prostate and bladder neck (which is why tadalafil treats BPH).

The drug profiles differ in half-life. Sildenafil's half-life is approximately 4 hours, giving it a clinical action of 4–6 hours. Tadalafil's half-life is approximately 17.5 hours, giving it a clinical action of up to 36 hours and making it suitable for once-daily continuous dosing — which is the regimen most relevant to the non-erection benefits discussed in this article [1].

Blood pressure: the established effect

PDE5 inhibitors lower blood pressure. This is not a side effect surprise — it is in the FDA label of every product in the class, and it is the reason both drugs are contraindicated with nitrate medications (where the combined NO/cGMP amplification can produce dangerous hypotension).

In healthy normotensive adults, a single dose of sildenafil 100 mg lowers systolic blood pressure by approximately 8 mmHg and diastolic by approximately 5 mmHg. Tadalafil 20 mg produces a comparable effect with a slower onset and longer duration. In hypertensive adults, the magnitude is similar or somewhat larger, and the effect is sustained with continuous daily dosing [2].

A 2024 meta-analysis pooling 14 RCTs of PDE5 inhibitors in patients with hypertension found a consistent reduction in clinic systolic BP of 5–9 mmHg and diastolic BP of 3–6 mmHg compared with placebo, with the largest effects in patients with the highest baseline pressures. Importantly, the BP-lowering effect is preserved when PDE5i are co-administered with standard antihypertensives (ACE inhibitors, ARBs, calcium channel blockers, thiazides) — though the combined effect requires clinician monitoring to avoid orthostatic hypotension.

This does not make tadalafil or sildenafil first-line antihypertensives. Neither is FDA-approved for essential hypertension in the general population, and the BP-lowering magnitude is modest compared with established agents — let alone the newer mechanism-targeted candidates like baxdrostat for resistant hypertension. But it does mean the drugs are best understood as vasodilators with a secondary erectile effect — not erection drugs with a secondary BP effect.

Endothelial function and vascular aging

Endothelial dysfunction — the impaired ability of the vascular endothelium to produce nitric oxide and respond to shear stress — is a hallmark of cardiovascular aging. It precedes atherosclerosis, predicts cardiovascular events, and is the unifying lesion across hypertension, diabetes, dyslipidemia, and smoking-related vascular injury. Flow-mediated dilation (FMD — an ultrasound measurement of brachial artery dilation following a period of cuff occlusion) is the standard non-invasive measure.

Multiple RCTs have shown that chronic PDE5 inhibitor therapy improves FMD in patients with established endothelial dysfunction. The magnitude is on the order of a 2–4 percentage point improvement in FMD over 4–12 weeks of daily dosing — a clinically meaningful change in a measure where every percentage point predicts cardiovascular risk [3]. The mechanism is mechanistically plausible beyond simple acute vasodilation: chronic PDE5 inhibition appears to upregulate endothelial nitric oxide synthase (eNOS) expression and reduce oxidative stress markers in the vessel wall.

The most consistent endothelial effect is seen with daily tadalafil 5 mg, which is the dose used for BPH and for continuous-dose erectile therapy. Sildenafil 50 mg three times weekly produces a similar but less consistent signal — the difference likely reflects the more sustained pharmacokinetic exposure of tadalafil.

These were vascular drugs first. The erection effect was a marketing pivot. The story the cardiovascular literature is now telling is the original one — modestly lowered blood pressure, improved endothelial function, and a mortality signal worth taking seriously.

Cardiovascular mortality: the observational signal

The most striking — and most carefully hedged — recent data is on all-cause and cardiovascular mortality in men prescribed PDE5 inhibitors. Multiple large observational cohort studies and pharmacoepidemiologic analyses since 2020 have found that men on PDE5 inhibitors have lower mortality than matched controls.

A UK general-practice cohort of 5,956 men with type 2 diabetes followed for a median 7.5 years (Anderson et al., Heart 2016) found that PDE5 inhibitor use was associated with an adjusted 46% reduction in all-cause mortality (hazard ratio 0.54, 95% CI 0.36–0.80) [4]. A separate Swedish national register analysis of men with prior myocardial infarction (Andersson DP et al., JACC 2021) reported lower all-cause and cardiovascular mortality with PDE5 inhibitor use versus alprostadil, with an apparent dose-response relationship — men with more PDE5i prescriptions over the follow-up window had lower mortality than men with fewer.

The honest reading of this evidence requires acknowledging the confounding-by-indication problem: men prescribed PDE5 inhibitors are, on average, healthier, more affluent, more compliant with medical care, and more likely to be sexually active — all of which independently predict longevity. Propensity score matching and active-comparator designs reduce but do not eliminate this confounding. No prospective RCT has tested whether PDE5 inhibitors reduce cardiovascular mortality as a primary endpoint, and one has not been ethically straightforward to design — but the consistent direction of the signal across multiple independent cohorts is hard to ignore.

The current expert reading is that PDE5 inhibitors are unlikely to be cardiovascularly harmful in appropriate patients, and may well be beneficial — but the magnitude of any true causal effect is almost certainly smaller than the observational estimates suggest. This is the kind of signal that warrants further study, not the kind that justifies off-label prescribing for cardiovascular prevention.

Pulmonary arterial hypertension — already FDA-approved

The clearest established non-erection use is pulmonary arterial hypertension (PAH — a progressive elevation of pressure in the pulmonary arteries that strains the right heart and causes exercise intolerance, syncope, and right heart failure if untreated). Sildenafil is FDA-approved for PAH under the brand name Revatio (20 mg three times daily — a much lower per-dose strength than the 50–100 mg used for ED). Tadalafil is FDA-approved for PAH under the brand name Adcirca (40 mg once daily).

In PAH, the mechanism is the same vasodilation, but the target tissue is the pulmonary vasculature. PDE5 is highly expressed in pulmonary smooth muscle, so PDE5 inhibition produces preferential pulmonary vasodilation with relatively modest systemic effects. Multiple RCTs have shown improved 6-minute walk distance, reduced pulmonary vascular resistance, and improved WHO functional class with PDE5 inhibitor therapy in PAH — making this class one of three first-line oral options for the disease (alongside endothelin receptor antagonists and prostacyclin pathway agents) [5].

Tadalafil and BPH: the urinary benefit

Tadalafil 5 mg once daily is FDA-approved for the symptoms of benign prostatic hyperplasia (BPH — non-cancerous enlargement of the prostate that constricts the urethra and causes lower urinary tract symptoms, including weak stream, urgency, frequency, and nocturia). The mechanism involves relaxation of smooth muscle in the prostate, bladder neck, and urethra — all of which express PDE5 — improving urinary flow and reducing irritative symptoms.

In the pivotal RCTs, daily tadalafil 5 mg produced approximately a 1.8–2.4 point placebo-corrected improvement in the International Prostate Symptom Score (IPSS — a validated 35-point questionnaire of urinary symptoms) over 12 weeks, with effects emerging within 1–2 weeks and sustained over 6+ months. The effect size is comparable to alpha-blocker monotherapy (tamsulosin), with a different side-effect profile and the additional benefit of erection support in men who have both BPH and erectile dysfunction [6]. This dual indication is the most common medical reason that men over 50 — many of whom are also navigating age-related testosterone decline — are prescribed continuous-dose tadalafil — and it is the regimen most relevant to the cardiovascular and endothelial benefits described above.

The Alzheimer's risk reduction hypothesis

Beginning in 2021, a series of large pharmacoepidemiologic analyses began reporting that sildenafil use was associated with a substantially lower incidence of Alzheimer's disease in older adults. A 2021 study in Nature Aging using a database of more than 7 million patient records found that sildenafil exposure was associated with a 69% reduction in Alzheimer's incidence over 6 years of follow-up, with effects observed across multiple comparator drug classes [7]. A 2024 UK primary-care cohort study (CPRD GOLD, Adesuyan et al., Neurology) of men with erectile dysfunction reported an 18% lower adjusted risk of Alzheimer's disease among PDE5 inhibitor initiators (hazard ratio 0.82, 95% CI 0.72–0.93) [12]. A separate 2024 Mendelian-randomization analysis using UK Biobank data found no causal association — illustrating why this signal remains observational rather than established.

The mechanistic hypothesis is plausible. PDE5 is expressed in brain tissue, and cGMP signaling is involved in synaptic plasticity, long-term potentiation, and clearance of beta-amyloid (the pathological protein aggregate central to Alzheimer's). Animal models of Alzheimer's have shown that sildenafil and tadalafil reduce amyloid plaque burden, improve memory performance, and enhance cerebral blood flow. Whether these effects translate to humans is the open question — and it is being tested in ongoing prospective trials, most notably a Phase 2 trial of sildenafil for early Alzheimer's at the Cleveland Clinic.

The same confounding-by-indication caveat applies. PDE5 inhibitor users are more sexually active, more medically engaged, and more cognitively reserved on average than non-users. Whether the Alzheimer's signal will survive prospective RCT testing remains unknown. But the consistency across independent cohorts, the mechanistic plausibility, and the size of the observational effect make this one of the more interesting drug-repurposing hypotheses currently in active clinical investigation.

Insulin sensitivity and metabolic data

Smaller mechanistic and short-term clinical trials have explored PDE5 inhibitor effects on insulin sensitivity and metabolic health. The hypothesis is that improved endothelial function and increased blood flow to peripheral tissues should improve insulin-mediated glucose uptake — and this is what early studies have shown.

A series of small RCTs in patients with type 2 diabetes have demonstrated improved insulin sensitivity (measured by hyperinsulinemic-euglycemic clamp or HOMA-IR) following 3–12 weeks of daily tadalafil 5–20 mg. Effect sizes are modest — typically a 10–20% improvement in HOMA-IR — and not all trials have been positive [8]. The clinical relevance for diabetes management is limited, but the signal contributes to a broader vascular-metabolic mechanism: improving endothelial function appears to have downstream metabolic benefits that go beyond simple BP reduction.

Animal data has also shown effects on adipose tissue browning (the conversion of energy-storing white adipose tissue toward more metabolically active beige/brown phenotypes) via cGMP signaling. Whether this translates to meaningful changes in human body composition is unstudied at the clinical level. The metabolic story is plausible but not yet established.

Contraindications and real side effects

The cardiovascular benefits do not erase the safety profile. PDE5 inhibitors have hard contraindications and meaningful side effects that must inform any clinical use.

Absolute contraindications:

• Nitrates of any kind. Nitroglycerin, isosorbide mononitrate or dinitrate, and recreational nitrites (poppers) all amplify the cGMP-mediated vasodilation to a dangerous degree. The combination can produce severe hypotension and cardiovascular collapse. This contraindication includes both regular use and as-needed nitrate use for angina — meaning patients with severe coronary artery disease who need sublingual nitroglycerin available cannot safely take PDE5 inhibitors.
• Soluble guanylate cyclase stimulators (riociguat) — used for pulmonary hypertension by a different mechanism, the combination amplifies cGMP to dangerous levels.
• Severe hepatic impairment (both drugs are hepatically metabolized via CYP3A4).
• Recent stroke, MI, or unstable angina (within 6 months).

Real side effects:

• Headache (10–15% of users), facial flushing (10%), dyspepsia (5–10%), nasal congestion (5%).
• Back and muscle pain — more common with tadalafil than sildenafil (5–10%).
• Visual disturbances — typically transient blue-tinged vision with sildenafil (sildenafil has weak cross-inhibition of PDE6, which is expressed in retinal photoreceptors).
• NAION (non-arteritic anterior ischemic optic neuropathy) — a rare but serious cause of sudden vision loss. Absolute risk is low but elevated in patients with cardiovascular risk factors and prior NAION history.
• Sudden hearing loss — also rare; reported in post-marketing surveillance; prompt drug discontinuation is recommended if it occurs.
• Priapism — prolonged painful erection requiring emergency treatment; more common with shorter-half-life agents but possible with any PDE5i.

The melanoma association reported in some earlier observational studies has been re-examined in larger analyses and is no longer considered a likely causal effect — the original signal is now attributed to confounding by skin-cancer risk factors (sun exposure, fair skin, affluence) that overlap with PDE5 inhibitor prescribing patterns [9].

A tiered framework